MDT
Medtronic PLC
Is MDT Halal?
Medical devices are generally permissible and the April 2026 annual financial ratios pass the examined total-assets limits, with product-level ethical review retained.
What You Should Know
Medtronic develops pacemakers, cardiac, surgical, neurological, diabetes and other medical devices. Its April 24, 2026 Form 10-K shows debt at 30.06% of total assets, identifiable liquidity at 9.93%, receivables plus cash at 9.24%, and interest income at 0.10% of fiscal-year net sales. Medical-device revenue is not a prohibited-category numerator, but product safety, clinical evidence and access remain qualitative questions.
⚠️ Concerns
- •Debt was 30.06% of total assets at April 24, 2026
- •Interest income was 0.10% of fiscal-year net sales
- •Medical-device safety, clinical outcomes, pricing, access, recalls, research ethics, labor, supply-chain and environmental impacts require qualitative review
Current quantitative Sharia screen
Based on 10-K figures for the period ended 2026-04-24; calculated 2026-07-14.
27,961 / 93,028
9,236 / 93,028
8,592 / 93,028
35 / 36,364
- Financial
- Pass
- Overall
- Pass
Debt/assets is 30.06%, liquidity/assets is 9.93%, receivables plus cash/assets is 9.24%, and disclosed interest income is 0.10%; the medical-device business input is a conservative permissible-business assessment.
- Financial
- Pass
- Overall
- Pass
The examined total-assets financial ratios pass; this is not an index-membership claim.
- Financial
- Pass
- Overall
- Pass
Debt/assets and identifiable liquidity/assets are below the examined 33% limits; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
Medtronic develops medical devices and therapies across cardiovascular, neuroscience, surgical, acute-care and diabetes markets. Medical technology that supports treatment and preserves health is generally permissible.
Limitation: The filing does not classify every customer, indication, reimbursement channel or downstream use; those remain qualitative review questions rather than an invented prohibited-revenue percentage.
Purification
Disclosed interest income is 0.10% of fiscal-year net sales; ZakatInvest does not prescribe a fixed purification percentage.
Inputs, assumptions and primary sources
- Amounts are USD millions from Medtronic's April 24, 2026 Form 10-K.
- Debt includes current debt obligations of $1,788 million and long-term debt of $26,173 million; operating lease liabilities are excluded.
- Cash is $1,949 million. Available-for-sale debt securities are $7,287 million; equity and other investments of $824 million are excluded from the interest-bearing-security numerator.
- Accounts receivable is $6,643 million and fiscal-year net sales are $36,364 million.
- Disclosed interest income is $35 million for fiscal 2026.
- Medtronic's disclosed operating segments are medical-device businesses; no prohibited operating category is identified in the filing, while product-specific ethics remain qualitative.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →